CJC-1295 and Thymosin Alpha-1 Stack: When to Pick One Over Both

What Each Peptide Actually Does, and Why Women Should Care Differently

The two compounds have nothing mechanistically in common. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells and amplifies the pulsatile release of growth hormone (GH). Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid fragment of prothymosin-alpha, secreted naturally by thymic epithelial cells, that acts on Toll-like receptor 9, dendritic cells, and T-helper pathways.

For you as a woman, both points of action carry sex-specific weight.

Growth Hormone and the Female Life Stage

GH secretion in women is not a flat baseline. Estrogen potentiates pituitary GH release, which is why premenopausal women generally have higher 24-hour GH secretion than age-matched men. During the reproductive years, GH pulses track loosely with the menstrual cycle, with higher amplitude in the follicular phase when estradiol is rising.

After menopause, GH secretion falls by roughly 50 percent compared with peak reproductive-age values, a decline that outpaces the male trajectory. This is not just about body composition. GH coordinates bone turnover, insulin sensitivity, lean mass maintenance, and skin collagen density. When estrogen drops at menopause, the GH axis loses its main amplifier.

GHRH analogues like CJC-1295 may therefore be disproportionately relevant in perimenopause and post-menopause, not because GH therapy is proven for these women, but because the underlying deficit is larger. A phase II trial by Ionescu and Frohman confirmed that exogenous GHRH-based peptides can substantially raise IGF-1 in healthy adults, though the study was not powered or stratified by menopausal status.

Thymosin Alpha-1 and Female Immune Patterns

Women are twice as likely as men to develop autoimmune disease, and the incidence peaks sharply during reproductive years when estrogen modulates T-regulatory and T-helper cell balance. Conditions such as Hashimoto's thyroiditis, lupus, rheumatoid arthritis, and multiple sclerosis skew heavily female.

Thymosin Alpha-1 was licensed in over 35 countries for hepatitis B and C based on its ability to augment antiviral T-cell responses. Its broader immunomodulatory profile, dampening excessive inflammatory signaling while improving surveillance against pathogens, has drawn interest in post-viral fatigue states (including long COVID), chronic infections, and immune senescence.

For women, there is an additional consideration: pregnancy shifts the immune system sharply toward Th2 tolerance to prevent fetal rejection. Thymosin Alpha-1's Th1-biasing effects make it incompatible with pregnancy (see the pregnancy section below).

The Case for Stacking Both

Stacking CJC-1295 with Thymosin Alpha-1 is not additive in the pharmacological sense. The two act on entirely separate receptor systems and there is no documented pharmacokinetic interaction. The rationale is purely clinical: you address two different deficits simultaneously.

The following framework helps identify who the combination is actually for. Think of it as three questions your clinician should ask before writing a protocol:

1. Is your primary complaint metabolic or immune in origin?
2. Do you have lab evidence of both GH-axis suppression (low IGF-1) and immune dysfunction (low NK-cell activity, recurrent infections, autoimmune flare)?
3. Are you willing to self-inject two separate compounds on overlapping but distinct schedules?

If your answer to question 1 is "both," to question 2 is "yes," and to question 3 is "yes," the stack is a defensible clinical experiment. If your primary complaint is clearly one-directional (poor recovery and body composition but normal immune markers, or chronic infection and fatigue with normal IGF-1), using a single agent first is simpler and makes adverse-event attribution easier.

Conditions Where the Stack Shows Up Clinically

Post-viral fatigue and long COVID. Practitioners in functional and integrative medicine have used this combination off-label in women presenting with post-COVID fatigue, brain fog, and muscle wasting. The hypothesized logic: Thymosin Alpha-1 addresses the T-cell exhaustion and immune dysregulation documented in long COVID, while CJC-1295 targets the GH-axis suppression that some studies associate with viral-illness-induced hypopituitarism. One observational case series published in Frontiers in Immunology documented immune dysregulation patterns in long COVID that are theoretically addressable by Thymosin Alpha-1, though the peptide was not used in that study.

Perimenopause with recurrent infection or post-COVID immune burden. Women in their 40s who are already experiencing estrogen fluctuation and GH-axis decline while managing a disrupted immune system represent the demographic most likely to be offered this stack in practice.

Cancer survivorship (off-label, post-treatment). Some oncology-adjacent integrative practitioners use Thymosin Alpha-1 to help rebuild immune surveillance after chemotherapy, pairing it with GHRH peptides to address the wasting that follows treatment. This is not a guideline-backed practice. It carries real risks, and decisions must be made in coordination with the treating oncologist.

When to Pick Just One

Choose CJC-1295 Alone When:

Your IGF-1 is measurably low (below the age-adjusted reference range), your complaint centers on body composition, recovery time, disrupted sleep architecture, or post-menopausal metabolic deceleration, and your immune markers are normal. Body composition changes during perimenopause are driven in part by declining GH pulsatility. A 2006 study in the Journal of Clinical Endocrinology and Metabolism confirmed that GH secretion declines across the menopausal transition independent of age. A targeted GHRH analogue is a cleaner intervention than a two-compound stack when the immune signal is absent.

Choose Thymosin Alpha-1 Alone When:

Your symptoms are dominantly immune: slow recovery from infections, confirmed low NK-cell activity, persistent viral illness, or a diagnosed autoimmune condition that your rheumatologist is comfortable with adjunctive immunomodulation. Thymosin Alpha-1 has the stronger evidence base as a single agent, given its licensed status in several countries and its trial record in HBV. Adding CJC-1295 when IGF-1 is normal does not add value and complicates monitoring.

Dosing and Protocol: What the Evidence Actually Supports

Neither compound has been studied in healthy women in a randomized controlled trial at the doses circulating in practice. Be clear-eyed about that. What follows is a synthesis of the pharmacokinetic data, licensed clinical doses, and documented research protocols, not a personal dosing prescription.

CJC-1295 Dosing

The most-cited research dose is 1,000 mcg (1 mg) subcutaneously, injected once or twice weekly when using the DAC (Drug Affinity Complex) form, which extends the half-life to 6 to 8 days. The non-DAC form (Modified GRF 1-29) has a half-life closer to 30 minutes and is typically dosed at 100 to 300 mcg per injection, often combined with a ghrelin mimetic like ipamorelin for synergistic GH pulse amplification.

Women-specific dosing considerations:

• Premenopausal women already have higher baseline GH pulsatility. Starting at the lower end of the range and checking IGF-1 at 6 to 8 weeks is sensible before titrating upward.
• Postmenopausal women on systemic estrogen therapy should be aware that estrogen itself amplifies GH secretion. The combination may push IGF-1 higher than anticipated.
• Women with PCOS who have androgen-dominant hormonal profiles show altered GH pulsatility. A study in the Journal of Clinical Endocrinology and Metabolism found suppressed GH pulsatility in women with PCOS, suggesting the GH axis is already disrupted. This makes monitoring more, not less, important.

Thymosin Alpha-1 Dosing

The licensed clinical dose, established in HBV treatment trials and used in countries where it is approved, is 1.6 mg subcutaneously twice weekly. Courses typically run 6 months for viral indications. Off-label immune-support protocols vary widely, with some practitioners using 500 mcg to 1 mg twice weekly for shorter cycles.

There is no phase II or III data in healthy women, PCOS, autoimmune thyroid disease, or any female-specific condition.

Stack Timing

Because CJC-1295 with DAC is dosed weekly or biweekly and Thymosin Alpha-1 is dosed twice weekly, they do not share injection days by necessity, though they can. The peptides are typically given as separate injections at separate sites because mixing them in the same syringe has not been studied for stability or compatibility.

A common practitioner-reported approach:

• Thymosin Alpha-1: Monday and Thursday subcutaneous, abdomen
• CJC-1295 (DAC): once weekly or every 10 to 14 days, subcutaneous, rotating sites

Labs to monitor: IGF-1 at baseline and 6 to 8 weeks, fasting glucose and insulin (CJC-1295 can transiently affect insulin sensitivity), CBC with differential (Thymosin Alpha-1 immune monitoring), thyroid function if autoimmune thyroid disease is in the background, and a comprehensive metabolic panel.

Female-Specific Conditions This Stack Touches

PCOS

Women with PCOS have a distinct metabolic-immune phenotype. Elevated androgens promote low-grade chronic inflammation, and insulin resistance is near-universal in the phenotype. Thymosin Alpha-1's anti-inflammatory signaling is hypothetically relevant. CJC-1295's effect on GH pulsatility, already disrupted in PCOS, warrants careful IGF-1 monitoring. No trials exist specifically in PCOS for either compound.

Hashimoto's Thyroiditis and Autoimmune Thyroid Disease

Hashimoto's is the most common autoimmune condition in women. Thymosin Alpha-1 has theoretical appeal given its T-regulatory effects, but no clinical trial has studied it specifically in Hashimoto's. Women with active thyroid autoimmunity who are considering Thymosin Alpha-1 should have thyroid peroxidase antibody (TPO-Ab) levels checked at baseline and at 3 months, so any directional change in antibody burden can be tracked.

Perimenopause and Post-Menopause

The dual deficit of GH-axis decline and age-related immune senescence makes perimenopausal and postmenopausal women the clearest theoretical candidates for the combined stack. GH secretion decline accelerates in the first 2 to 3 years after final menstrual period. Thymic involution, which reduces Thymosin Alpha-1 production naturally, also accelerates with age. The stack attempts to partially replace two age-related deficits simultaneously.

This logic is mechanistically sound. The absence of RCT data in this population means the benefit-risk calculation remains a clinical judgment call, not a proven therapy.

Female Pattern Hair Loss

CJC-1295 is sometimes marketed for hair as GH supports dermal papilla cell proliferation. There is no trial evidence for this in women. Women losing hair should have a standard androgenic and nutritional workup (ferritin, DHEA-S, testosterone, thyroid, zinc) before considering off-label peptide use for hair.

Pregnancy, Lactation, and Contraception

This section is not optional to read.

Neither CJC-1295 nor Thymosin Alpha-1 has been studied in pregnant women. Both are excluded from pregnancy and lactation by absence of safety data and biological plausibility of harm.

CJC-1295 in pregnancy: GHRH and GH signaling are tightly regulated during pregnancy. Exogenous GHRH peptides could theoretically disrupt placental GH production, which is produced by the syncytiotrophoblast rather than the pituitary after the first trimester. Placental GH drives fetal growth factor signaling. Interfering with this system carries an unknown but non-zero risk of fetal growth abnormality. Animal reproductive toxicology studies are not available in the public literature for this specific compound.

Thymosin Alpha-1 in pregnancy: Pregnancy survival depends on the maternal immune system tolerating a semi-allogeneic fetus, primarily through Th2 dominance and T-regulatory cell expansion. Thymosin Alpha-1 is a Th1-biasing agent. Introducing strong Th1 immune activation during pregnancy may theoretically increase the risk of implantation failure, miscarriage, or preterm labor, mechanisms associated with Th1-dominant immune states in early pregnancy research. ACOG recommends against use of investigational immune-active agents in pregnancy outside of clinical trials.

Contraception requirement: If you are using either compound and are of reproductive age and not menopausal, use effective contraception throughout the treatment period and for at least one full menstrual cycle (minimum 4 weeks) after stopping. Discuss the washout period with your prescriber before any planned conception attempt.

Lactation: Neither compound has lactation transfer data. Excretion in breast milk is unknown. Do not use while breastfeeding.

Fertility note: There is no evidence that these peptides are fertility-enhancing, despite their appearance in some wellness spaces alongside fertility claims. CJC-1295 increases GH and IGF-1, which can interact with ovarian follicle maturation, but this does not translate to improved ovulation rates in the absence of a documented GH-axis deficit. If you are trying to conceive, stop both compounds and seek care through a reproductive endocrinologist.

Who This Stack Is Right For, and Who It Is Not

Potentially appropriate (with medical supervision):

• Postmenopausal women with documented low IGF-1 and confirmed immune dysfunction (recurrent infection, low NK-cell activity) who have been cleared for off-label peptide therapy
• Women in recovery from documented viral illness with measurable GH-axis suppression and immune marker changes
• Perimenopausal women with combined metabolic and immune complaints and willingness to monitor labs every 6 to 8 weeks

Likely not appropriate:

• Women who are pregnant, trying to conceive, or breastfeeding (see above, no exceptions)
• Women with active hormone-sensitive cancers: GH and IGF-1 elevation may stimulate growth in IGF-1 receptor-expressing tumors
• Women with uncontrolled type 2 diabetes: CJC-1295 raises GH, which is counter-regulatory to insulin, and can worsen glycemic control
• Women with active autoimmune flare who are on biologic therapy: the interaction between Thymosin Alpha-1 and agents like anti-TNF biologics is unstudied
• Women seeking these peptides for cosmetic body recomposition without metabolic indication: the risk-benefit calculation is unfavorable when there is no measurable deficit to correct

Evidence Gaps You Should Know Before You Commit

Women have been systematically underrepresented in peptide research. The foundational GHRH analogue work by Ionescu and Frohman included both sexes but was not powered to detect sex-specific differences in IGF-1 response. Thymosin Alpha-1's licensed trials in hepatitis were predominantly male in demographic. Neither compound has a female-specific phase II trial, a trial in PCOS, a trial in perimenopause, or a trial in postmenopausal women.

What practitioners are drawing on when they prescribe this stack is a combination of receptor-level mechanistic logic, animal studies, small observational human data, and clinical experience. That is a real evidence base. It is not the same as RCT-level certainty. A woman asking her prescriber for the evidence should expect an honest answer that includes "we are extrapolating."

The FDA's guidance on compounded peptides notes that CJC-1295 and similar GHRH analogues currently occupy a regulatory gray zone in the United States as compounded preparations, with evolving enforcement status. Verify the current status with your prescriber before starting.

Practical Questions Before You Start

Ask your prescriber these four questions and expect specific answers, not reassurance:

1. What is my current IGF-1 level and how does it compare to the reference range for my age and menopausal status?
2. What immune marker are we targeting, and what will we measure at 8 weeks to decide whether to continue?
3. What is the protocol for stopping if I want to try for pregnancy or if a pregnancy occurs unexpectedly?
4. Is my compounder third-party tested for sterility, endotoxin, and peptide identity?

If a prescriber cannot answer all four questions with specific numbers and lab names, find a different prescriber.